These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19707349)

  • 1. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Biologics; 2007 Mar; 1(1):59-68. PubMed ID: 19707349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Lafreniere R; Weir DM
    Autoimmunity; 2012 Nov; 45(7):495-509. PubMed ID: 22816962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Int J Exp Pathol; 2004 Dec; 85(6):321-34. PubMed ID: 15566429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The modified vaccination technique designed to prevent and cure acute and chronic disorders.
    Barabas AZ; Cole CD; Kovacs ZB; Kovacs EI; Lafreniere R; Weir DM
    Hum Antibodies; 2020; 28(2):111-121. PubMed ID: 31594214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Ann N Y Acad Sci; 2007 Sep; 1110():619-29. PubMed ID: 17911477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Pathol Int; 2006 Apr; 56(4):181-90. PubMed ID: 16634963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.
    Barabas AZ; Cole CD; Graeff RM; Lafreniere R; Weir DM
    Immunol Res; 2017 Feb; 65(1):402-409. PubMed ID: 27456203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease.
    Barabas AZ; Lafreniere R
    Autoimmun Rev; 2005 Nov; 4(8):565-70. PubMed ID: 16214097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders.
    Barabas AZ; Cole CD; Barabas AD; Graeff RM; Lafreniere R; Weir DM
    Scand J Immunol; 2010 Mar; 71(3):125-33. PubMed ID: 20415778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis.
    Barabas AZ; Cole CD; Barabas AD; Barabas AN; Lafreniere R
    Pathol Int; 2006 Sep; 56(9):516-29. PubMed ID: 16930332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique.
    Barabas AZ; Cole CD; Barabas AD; Graeff RM; Lafreniere R; Weir DM
    Autoimmun Rev; 2009 Jun; 8(7):552-7. PubMed ID: 19393215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes.
    Barabas AZ; Cole CD; Sensen M; Lafreniere R
    Int J Exp Pathol; 2012 Feb; 93(1):11-7. PubMed ID: 22103575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated antibody response by antigen presentation in immune complexes.
    Barabas AZ; Cole CD; Kovacs ZB; Lafreniere R
    Med Sci Monit; 2007 May; 13(5):BR119-24. PubMed ID: 17476190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing and treating chronic disorders using the modified vaccination technique.
    Barabas AZ; Weir DM; Cole CD; Barabas AD; Bahlis NJ; Graeff RM; Lafreniere R
    Front Biosci (Landmark Ed); 2009 Jan; 14(10):3892-8. PubMed ID: 19273320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regaining tolerance to a self-antigen by the modified vaccination technique.
    Barabas AZ; Cole CD; Lafreniere R; Weir DM
    Clin Rev Allergy Immunol; 2013 Oct; 45(2):193-201. PubMed ID: 23296949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen.
    Barabas AZ; Cole CD; Graeff RM; Morcol T; Lafreniere R
    Hum Antibodies; 2016; 24(3-4):45-51. PubMed ID: 28128764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique.
    Barabas AZ; Cole CD; Barabas AD; Barabas AN; Lafreniere R
    Clin Dev Immunol; 2006 Mar; 13(1):17-24. PubMed ID: 16603441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of Heymann nephritis by a chemically modified renal antigen.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Int J Exp Pathol; 2004 Oct; 85(5):277-85. PubMed ID: 15379960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of a new model of slowly progressive Heymann nephritis.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Int J Exp Pathol; 2003 Dec; 84(6):245-58. PubMed ID: 14748744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New vaccination technology for endogenous antigen-derived ailments.
    Barabas AZ; Cole CD; Barabas AD; Bahlis NJ; Lafreniere R
    IDrugs; 2008 Feb; 11(2):111-5. PubMed ID: 18240096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.